Clinical Trials in Chronic Liver Disease - What Do They Achieve? | Zendy

Jenny Heathcote | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Trials in Chronic Liver Disease - What Do They Achieve?

Author(s) -

Jenny Heathcote

Publication year - 2004

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2004/748749

Subject(s) - clinical trial , disease , medicine , chronic liver disease , intensive care medicine , drug development , alternative medicine , liver disease , agency (philosophy) , drug , pharmaceutical industry , pathology , pharmacology , cirrhosis , philosophy , epistemology

The past 30 years have seen rapid growth in the number of clinical trials in liver disease; due mostly to effective drug discovery programs by the pharmaceutical industry. The advantages associated with therapeutic trials in chronic liver disease, or any other disease for that matter, go far beyond potential benefit to the individual patient, other beneficiaries include the treating physician, the sponsoring agency and their investors, the institution/university and the general public. But there is always a downside to any experiment. The disadvantages and advantages of clinical trials in liver disease are the topics for this discussion

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research